Lycera

Lycera is a biopharmaceutical company that is developing new small molecule immunomodulatory medicines for the treatment of autoimmune diseases and cancer. Based on a world-class R&D engine, the Company has built a portfolio of selective immune modulators that promise substantial advances in treatment, not simply incremental gains, and offer novel mechanisms of action to deliver improved efficacy and safety profiles.

We are advancing clinical candidates from distinct, yet complementary, areas of research, including immune metabolism, cell signaling, and immune cell differentiation. Lycera’s lead product candidate, an oral, gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, is currently in Phase 1 clinical testing.  The Company also has a leading position in the development of agonists of RORγ, a master transcription factor, or “master control switch,” with diverse applications in immune-oncology. Further, the effectiveness of Lycera’s drug discovery operations has been validated by research collaborations with Merck.

Lycera’s product development programs are constructed carefully to leverage the broad-ranging expertise of our integrated research teams, enhanced by our established relationships with renowned thought leaders and clinical researchers worldwide.